Innovation Activities and Developments

For clinical research stakeholders, implementing and scaling electronic source date (eSource) is a priority. With participation from MSK, a number of Society of Clinical Data Management (SCDM) working groups have collaborated on a paper outlining consensus recommendations on eSource best practices.

On Tuesday, December 2, MSK hosted "Demo Day 2025," a strong follow-up to the institution’s November 2025 “Innovation with Lasting Impact Summit” on entrepreneurship and innovation.

MSK is a founding member of the Cancer AI Alliance (CAIA), an exciting collaborative research initiative designed to accelerate development and deployment of AI models to improve cancer care. This unique alliance unites four leading NCI-designated cancer centers — MSK, Dana-Farber Cancer Institute, Fred Hutch Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins — with technology powerhouses that include Ai2, Amazon, Deloitte, Google, Microsoft, Nvidia, and Slalom.

On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.

Memorial Sloan Kettering Cancer Center (MSK) is collaborating with Triomics, an oncology-focused generative artificial intelligence company, to deploy Triomics’ artificial intelligence (AI)-powered clinical trial matching and screening platform in MSK’s active clinical trials.

May is Clinical Trials Awareness Month, culminating on May 20 with International Clinical Trials Day. For institutions like ours, this is an opportunity to commemorate the importance of clinical research and the valued contributions of clinical research professionals around the world.

For the first time, MSK has been named one of Fast Company’s Best Workplaces for Innovators, ranking No. 9 out of 100 on its 2025 list of awardees.

Memorial Sloan Kettering Cancer Center (MSK) recently executed a contract with HealthLinx, a consulting firm that helps hundreds of hospitals achieve Magnet® and Pathway to Excellence ® designation. Under the agreement, MSK’s EBP Consulting Service will provide training in MSK’s proprietary evidence-based practice (EBP) methodology directly to select HealthLinx clients who are looking to improve or enculturate EBP.

Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

Danny Khalil, MD, PhD, medical oncologist and immunotherapy specialist at Memorial Sloan Kettering Cancer Center (MSK), has won a 2025 Scholar-Innovator Award from the Harrington Discovery Institute.